15:58 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arterial thrombosis S100 calcium binding protein A9 (S100A9; calgranulin B; MRP14) Studies in mice and patients suggest S100A9 inhibitors could help prevent arterial thrombosis....
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in mice and patients suggest depleting tumor stroma and...
07:00 , May 29, 2014 |  BC Innovations  |  Targets & Mechanisms

S100A9-clot not, bleed not

Although the new generation of antithrombotic drugs provides marked improvements over warfarin, they all still carry bleeding risk. S100 calcium binding protein A9 could represent a new target that, when blocked, prevents thrombosis without increasing...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

Paquinimod regulatory update

Active Biotech disclosed in its 1Q14 earnings that in January FDA granted Orphan Drug designation to paquinimod to treat systemic sclerosis. The small molecule quinoline-3-carboxamide immunomodulator is in Phase I testing and has Orphan Drug...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Paquinimod: Phase I started

Active Biotech disclosed in its 4Q11 earnings that in November it began an open-label Phase I trial to evaluate paquinimod in 10-20 patients. The product has Orphan Drug designation in Europe to treat systemic sclerosis....
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

Paquinimod regulatory update

In February, EMA granted Orphan Drug designation for Active Biotech's paquinimod to treat systemic sclerosis. The small molecule quinoline-3-carboxamide immunomodulator is slated to begin Phase IIa testing for the indication this year. Active Biotech AB...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

Paquinimod: Phase II data

An exploratory, open-label, Swedish and Danish Phase II trial in 13 patients with mild active SLE showed that once-daily 1.5 and 3 mg oral paquinimod for 12 weeks as an add-on to standard therapy led...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

Paquinimod regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation for Active Biotech's paquinimod to treat systemic sclerosis. The quinoline-3-carboxamide is in preclinical testing for the indication. COMP is part of the European Medicines...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc. , the outcome hardly looked like a slam dunk. Based on a pair...